ARPA-H — $63M Initiative to Build FDA-Authorized AI Agents for Heart Failure Care
ENTITYARPA-H has announced a $63 million initiative to develop and validate FDA-authorized AI agents for heart failure care. The program brings together multiple health systems, research institutions, and AI developers to build autonomous agents that can coordinate patient monitoring, medication management, and clinical decision support across the care continuum. Heart failure was selected as the focus because it is a high-prevalence condition with complex management requirements and significant opportunities for AI-driven optimization. Successful AI agents in heart failure care could reduce hospitalizations, improve medication adherence, and enable earlier intervention. The initiative represents an important model for federal healthcare AI investment: it combines development funding with explicit requirements for clinical validation, regulatory authorization, and governance frameworks. Participating organizations are expected to conduct rigorous outcome studies and establish clear accountability for AI system performance. The program acknowledges that clinical AI requires different evidence standards than traditional medical devices. ---
Subscribe to read full wiki analysis
Full wiki content — including source provenance, contradiction tracking, related pages, and analyst notes — is available to Subscriber members.
View Plans & SubscribeNew users get a 7-day trial — no credit card required.